AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

NASDAQ:IMGNImmunoGen Stock Price, Forecast & News

$4.80
-0.06 (-1.23 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.77
Now: $4.80
$5.13
50-Day Range
$3.39
MA: $4.07
$5.34
52-Week Range
$1.76
Now: $4.80
$7.07
Volume200,311 shs
Average Volume2.43 million shs
Market Capitalization$837.17 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Read More
ImmunoGen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IMGN
CUSIP45253H10
Phone781-895-0600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$82.27 million
Book Value($0.02) per share

Profitability

Net Income$-104,130,000.00
Net Margins-102.87%

Miscellaneous

Employees296
Market Cap$837.17 million
Next Earnings Date8/7/2020 (Estimated)
OptionableOptionable

Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter.

ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

How has ImmunoGen's stock been impacted by COVID-19 (Coronavirus)?

ImmunoGen's stock was trading at $3.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IMGN stock has increased by 42.4% and is now trading at $4.80. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ImmunoGen?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ImmunoGen.

When is ImmunoGen's next earnings date?

ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for ImmunoGen.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) issued its quarterly earnings data on Friday, May, 1st. The biotechnology company reported ($0.17) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.02. The biotechnology company earned $13.29 million during the quarter, compared to analysts' expectations of $14.53 million. View ImmunoGen's earnings history.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen updated its FY 2020 Pre-Market earnings guidance on Friday, May, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $60-65 million, compared to the consensus revenue estimate of $62.72 million.

What price target have analysts set for IMGN?

4 Wall Street analysts have issued 12 month target prices for ImmunoGen's stock. Their forecasts range from $9.00 to $12.00. On average, they anticipate ImmunoGen's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 118.8% from the stock's current price. View analysts' price targets for ImmunoGen.

Has ImmunoGen been receiving favorable news coverage?

News stories about IMGN stock have trended very negative on Thursday, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ImmunoGen earned a news impact score of -3.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutImmunoGen.

Who are some of ImmunoGen's key competitors?

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Immunomedics (IMMU), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), NVIDIA (NVDA), Opko Health (OPK), Amarin (AMRN) and Exelixis (EXEL).

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the following people:
  • Mr. Mark J. Enyedy, Pres, CEO, Interim Principal Financial Officer & Director (Age 55)
  • Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 61)
  • Mr. Craig Barrows, Exec. VP, Gen. Counsel & Sec. (Age 64)
  • Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 49)
  • Mr. David G. Foster, VP of Fin. & Chief Accounting Officer

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (10.98%), Redmile Group LLC (9.59%), BlackRock Inc. (7.81%), Clearbridge Investments LLC (4.76%), State Street Corp (3.28%) and RA Capital Management L.P. (2.96%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Craig Barrows, David Brannon Johnston, David G Foster, Mark Alan Goldberg, Mark J Enyedy, Richard J Gregory and Thomas Ryll. View institutional ownership trends for ImmunoGen.

Which major investors are selling ImmunoGen stock?

IMGN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Primecap Management Co. CA, Clearbridge Investments LLC, Invesco Ltd., JPMorgan Chase & Co., Squarepoint Ops LLC, and Raymond James & Associates. Company insiders that have sold ImmunoGen company stock in the last year include Craig Barrows, David G Foster, Mark J Enyedy, and Thomas Ryll. View insider buying and selling activity for ImmunoGen.

Which major investors are buying ImmunoGen stock?

IMGN stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, RA Capital Management L.P., Redmile Group LLC, BlackRock Inc., Deutsche Bank AG, Nuveen Asset Management LLC, Healthcare of Ontario Pension Plan Trust Fund, and State Street Corp. View insider buying and selling activity for ImmunoGen.

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $4.80.

How big of a company is ImmunoGen?

ImmunoGen has a market capitalization of $837.17 million and generates $82.27 million in revenue each year. The biotechnology company earns $-104,130,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. ImmunoGen employs 296 workers across the globe.

What is ImmunoGen's official website?

The official website for ImmunoGen is www.immunogen.com.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.